Novo Nordisk, a one-time leader in weight loss drugs, is currently experiencing stiff competition from Lilly. Insights from former Novo employees indicate that the company’s conservative stance towards obesity drugs may be the reason for its lagging behind Lilly in a market that is projected to surpass the $100 billion mark by the end of […]
Tag: Novo Nordisk
Semaglutide Linked to Rare Vision-Loss Disorder, European Regulators Report
The European Medicines Agency’s (EMA) safety committee, the Pharmacovigilance Risk Assessment Committee (PRAC), has concluded its in-depth investigation into medicines containing semaglutide, following concerns surrounding an increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION). This eye condition is a rare vision-loss disorder that can potentially cause significant vision loss. The comprehensive review by […]
Positive Results in Biotech Tests: RGX-202 Improves Muscle Function
The biotech industry has been abuzz with the latest results from the testing of RegenxBio’s RGX-202. The promising outcomes from the study, reported in November 2024, highlight the treatment’s potential to enhance muscle function in patients, particularly in tasks like walking, rising, and stair-climbing. These positive results, based on improvements in muscle function in boys […]